Trials / Completed
CompletedNCT03990311
Prepared Meals to Prime and Perpetuate Reduced Dietary Sodium Intake in Hemodialysis
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Tufts Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized clinical trial in which maintenance hemodialysis patients will be provided with salt restricted 'dialysis friendly' meals and compared to a control arm receiving usual care.
Detailed description
Patients randomized to the intervention arm will receive 2 months of meals plus dietary counseling. Counseling will continue for an additional 3 months while the control arm will have 5 months of usual care followed by 2 months of meal provision. Effects on interdialytic weight gain, achievement of target dry weight, intradialytic hypotension episodes, blood pressure, and a volume assessment using lung U/S to assess lung water will be measured. Salt sensitivity will be tested throughout the study. Self reported questionnaires about the burden of adhering to the low salt diet and the level of adherence with it will be completed at baseline and throughout the study. The investigator hypothesizes that the prepared meals with prime patients behavior and may alter salt taste perception and that these effects will be sustained after the prepared meals have stopped.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Sodium Restricted Meals | 2 meals prepared with 2 g /day sodium restriction and adhering to dietary recommendations for a hemodialysis patients (phosphate and potassium restricted/ high protein content) 2 meals per day for first month of meal provision period followed by 1 meal per month in the second meal of meal provision period |
| OTHER | Control | Usual Care |
Timeline
- Start date
- 2019-06-05
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2019-06-18
- Last updated
- 2023-01-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03990311. Inclusion in this directory is not an endorsement.